scholarly journals Long-term outcome of a patient with Transcobalamin deficiency caused by the homozygous c.1115_1116delCA mutation in TCN2 gene: a case report

Author(s):  
Francesco Martino ◽  
Alessandra Magenta ◽  
Maria Letizia Troccoli ◽  
Eliana Martino ◽  
Concetta Torromeo ◽  
...  

Abstract Background: Transcobalamin deficiency is a rare autosomal recessive inborn error of cobalamin transport (prevalence: <1/1000000) which clinically manifests in early infancy. Case presentation:We describe the case of a 30 year old woman who at the age of 30 days presented with the classical clinical and laboratory signs of an inborn error of vitamin B12 metabolism. Family history revealed a sister who died at the age of 3 months with a similar clinical syndrome and with pancytopenia. She was started on empirical intramuscular (IM) cobalamin supplements (injections of hydroxocobalamin 1 mg/day for 1 week and then 1 mg twice a week) and several transfusions of washed and concentrated red blood cells.With these treatments a clear improvement in symptoms was observed, with the disappearance of vomiting, diarrhea and normalization of the full blood count. At 8 years of age injections were stopped for 3 months causing the reappearance of megaloblastic anemia. IM hydroxocobalamin was then restarted sine die. The definitive diagnosis could only be established at 29 years of age when a genetic evaluation revealed the homozygous c.1115_1116delCA mutation of TCN2 gene (p.Q373GfsX38).Currently she is a 30-year old healthy lady taking 1 mg of IM hydroxocobalamin once a week.Conclusions: Our case report highlights that early detection of TC deficiency and early initiation of aggressive IM treatment is likely associated with disease control and an overall favorable outcome.

2021 ◽  
Author(s):  
Francesco Martino ◽  
Alessandra Magenta ◽  
Maria Letizia Troccoli ◽  
Eliana Martino ◽  
Concetta Torromeo ◽  
...  

Abstract Background: Transcobalamin deficiency is a rare autosomal recessive inborn error of cobalamin transport (prevalence: <1/1000000) which clinically manifests in early infancy.Case presentation: We describe the case of a 31 years old woman who at the age of 30 days presented with the classical clinical and laboratory signs of an inborn error of vitamin B12 metabolism. Family history revealed a sister who died at the age of 3 months with a similar clinical syndrome and with pancytopenia. She was started on empirical intramuscular (IM) cobalamin supplements (injections of hydroxocobalamin 1 mg/day for 1 week and then 1 mg twice a week) and several transfusions of washed and concentrated red blood cells. With these treatments a clear improvement in symptoms was observed, with the disappearance of vomiting, diarrhea and normalization of the full blood count. At 8 years of age injections were stopped for about two and a half months causing the appearance of pancytopenia. IM hydroxocobalamin was then restarted sine die. The definitive diagnosis could only be established at 29 years of age when a genetic evaluation revealed the homozygous c.1115_1116delCA mutation of TCN2 gene (p.Q373GfsX38).Currently she is healthy and she is taking 1 mg of IM hydroxocobalamin once a week.Conclusions: Our case report highlights that early detection of TC deficiency and early initiation of aggressive IM treatment is likely associated with disease control and an overall favorable outcome.


2021 ◽  
Vol 47 (1) ◽  
Author(s):  
Francesco Martino ◽  
Alessandra Magenta ◽  
Maria Letizia Troccoli ◽  
Eliana Martino ◽  
Concetta Torromeo ◽  
...  

Abstract Background Transcobalamin deficiency is a rare autosomal recessive inborn error of cobalamin transport (prevalence: < 1/1000000) which clinically manifests in early infancy. Case presentation We describe the case of a 31 years old woman who at the age of 30 days presented with the classical clinical and laboratory signs of an inborn error of vitamin B12 metabolism. Family history revealed a sister who died at the age of 3 months with a similar clinical syndrome and with pancytopenia. She was started on empirical intramuscular (IM) cobalamin supplements (injections of hydroxocobalamin 1 mg/day for 1 week and then 1 mg twice a week) and several transfusions of washed and concentrated red blood cells. With these treatments a clear improvement in symptoms was observed, with the disappearance of vomiting, diarrhea and normalization of the full blood count. At 8 years of age injections were stopped for about two and a half months causing the appearance of pancytopenia. IM hydroxocobalamin was then restarted sine die. The definitive diagnosis could only be established at 29 years of age when a genetic evaluation revealed the homozygous c.1115_1116delCA mutation of TCN2 gene (p.Q373GfsX38). Currently she is healthy and she is taking 1 mg of IM hydroxocobalamin once a week. Conclusions Our case report highlights that early detection of TC deficiency and early initiation of aggressive IM treatment is likely associated with disease control and an overall favorable outcome.


2020 ◽  
Author(s):  
Francesco Martino ◽  
Alessandra Magenta ◽  
Maria Letizia Troccoli ◽  
Eliana Martino ◽  
Concetta Torromeo ◽  
...  

Abstract Background:Transcobalamin deficiency is a rare autosomal recessive inborn error of cobalamin transport (prevalence: <1/1000000)whichclinically manifests in early infancy. Case presentation:We describe the case of a 30 year old woman who at the age of 30 days presented with the classical clinical and laboratory signs of an inborn error of vitamin B12 metabolism. Family history revealed a sister who died at the age of 3 months with a similar clinical syndrome and with pancytopenia.Shewas started on empirical intramuscular (IM) cobalamin supplements (injections of hydroxocobalamin 1 mg/day for 1 week and then 1 mg twice a week) and several transfusions of washed and concentrated red blood cells.With thesetreatments a clear improvement in symptoms was observed, with the disappearance of vomiting, diarrhea and normalization of the full blood count.At 8 years of age injections were stopped for 3 monthscausing the reappearance of megaloblastic anemia.IM hydroxocobalamin was then restartedsine die.The definitive diagnosis could only be established at 29 years of age when a genetic evaluation revealed homozygous nonsense variation in exon 8 of the TCN2 gene.Currently she is a 30-year old healthy lady taking 1 mg of IM hydroxocobalamin once a week.Conclusions: Our case report highlights that early detection of TC deficiency and early initiation of aggressive IM treatment is likely associated with disease control and an overall favorable outcome.


2019 ◽  
Vol 29 (4) ◽  
pp. 528-530
Author(s):  
Ellen S. I. Vanhie ◽  
Ad J. J. C. Bogers ◽  
Willem A. Helbing

AbstractTricuspid valvectomy is a rare surgical intervention, and knowledge regarding long-term outcome in children is lacking. We report a favourable outcome 11 years after tricuspid valvectomy in early infancy without subsequent surgery or other cardiac interventions. Specific criteria for timing of re-intervention are lacking. Application of adult tricuspid and pulmonary regurgitation recommendations is helpful but has limitations.


2001 ◽  
Vol 21 (13) ◽  
pp. 1111-1113 ◽  
Author(s):  
Nancy Steinberg Warren ◽  
Shirley Soukup ◽  
Jennifer L. King ◽  
Peter St. J. Dignan

2017 ◽  
Vol 56 (3) ◽  
pp. 638-642 ◽  
Author(s):  
Ilias Bisbinas ◽  
Zacharoula Karabouta ◽  
Vasileios Lampridis ◽  
Dimitrios Georgiannos ◽  
Athanasios Badekas

2021 ◽  
Vol 9 (19) ◽  
pp. 5252-5258
Author(s):  
Zi-Xuan Zhuang ◽  
Ming-Tian Wei ◽  
Xu-Yang Yang ◽  
Yang Zhang ◽  
Wen Zhuang ◽  
...  

2016 ◽  
Vol 6 (21) ◽  
pp. 49-51
Author(s):  
Dan Cristian Gheorghe ◽  
Adina Zamfir-Chiru-Anton

Abstract Tumors of the maxillary sinus pose difficult challenges in a young patient. Our paper presents a very rare case of an odontogenic myxoma extended to the maxillary sinus, in a 14-year-old girl. The clinical picture suggested a malignancy or a local infection. The surgical removal was complete and the diagnosis was confirmed by immunohistochemistry. Discussions are made from the perspective of already published cases. A review of the disease is performed. CONCLUSION. Myxoma is a benign but aggressive tumor, needing complete surgical excision for a good long-term outcome.


Sign in / Sign up

Export Citation Format

Share Document